BENJAMIN MATTHEW SEGAL, M.D.
Neurology in Ann Arbor, MI
License number
Michigan 4301090951
Category
Social Work
Type
Clinical Neuropsychologist
License number
Michigan 185304
Category
Neurology
Type
Neurology
License number
Michigan 4301090951
Category
Neurology
Type
Neurology
Address
Address
1500 Floor Taubman Ctr, Ann Arbor, MI 48109
Phone
(734) 936-9010
(734) 936-2047
(734) 936-2047
Personal information
See more information about BENJAMIN MATTHEW SEGAL at radaris.comName
Address
Phone
3517 Comanche Ave, Flint, MI 48507
315 2Nd St APT 214, Ann Arbor, MI 48103
Professional information
See more information about BENJAMIN MATTHEW SEGAL at trustoria.com
Dr. Benjamin M Segal, Ann Arbor MI - MD (Doctor of Medicine)
Dr. Benjamin M Segal, Ann Arbor MI - MD (Doctor of Medicine)
Specialties:
Neuropsychiatry (Neurology)
Address:
U OF M TAUBMAN CENTER MEDICAL CLINIC
1500 E Medical Center Dr SUITE 5322, Ann Arbor 48109
(734) 936-9010 (Phone), (734) 615-4991 (Fax)
1500 E Medical Center Dr SUITE 5322, Ann Arbor 48109
(734) 936-9010 (Phone), (734) 615-4991 (Fax)
Certifications:
Neurology, 1994
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
U OF M TAUBMAN CENTER MEDICAL CLINIC
1500 E Medical Center Dr SUITE 5322, Ann Arbor 48109
University of Michigan Health System
1500 East Medical Center Dr SPC 5474, Ann Arbor 48109
1500 E Medical Center Dr SUITE 5322, Ann Arbor 48109
University of Michigan Health System
1500 East Medical Center Dr SPC 5474, Ann Arbor 48109
Education:
Medical School
Brown University / Alpert Medical School
Graduated: 1988
Brown University / Alpert Medical School
Graduated: 1988
Lymphoid Chemokines In The Diagnosis, Monitoring And Treatment Of Inflammatory Disease
Lymphoid Chemokines In The Diagnosis, Monitoring And Treatment Of Inflammatory Disease
US Patent:
8546538, Oct 1, 2013
Filed:
Apr 9, 2008
Appl. No.:
12/100196
Inventors:
Benjamin M. Segal - Ann Arbor MI, US
Ludmila Bagaeva - Fairport NY, US
Ludmila Bagaeva - Fairport NY, US
Assignee:
University of Rochester - Rochester NY
International Classification:
C07K 16/00, A61K 39/395
US Classification:
5303871, 4241301
Abstract:
Experimental autoimmune encephalomyelitis (EAE) is a Th1-mediated autoimmune disease of the central nervous system that is widely used as an animal model of multiple sclerosis (MS). In this study it was demonstrate that CXCL13, a chemokine involved in the development of secondary lymphoid tissues, is expressed in CD11c+ myeloid cells that accumulate in EAE lesions. Blockade or deficiency of CXCL13 ameliorates clinical EAE, both during acute and relapsing stages. CXCL13 deficiency did not inhibit the priming or differentiation of autoimmune effector T-cells in the periphery, but appeared to exert its effects during the effector phase of pathogenesis. These findings indicate that reagents that antagonize or inhibit CXCL13 are useful for the treatment of neuroinflammatory diseases such as MS.
Compositions And Methods For Inhibiting G-Csfr
Compositions And Methods For Inhibiting G-Csfr
US Patent:
2011011, May 19, 2011
Filed:
Oct 18, 2010
Appl. No.:
12/906548
Inventors:
Benjamin M. Segal - Ann Arbor MI, US
Praveen Rao - Ann Arbor MI, US
Praveen Rao - Ann Arbor MI, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF MICHIGAN - Ann Arbor MI
International Classification:
A61K 39/395, C07K 16/24, C07H 21/02, C07H 21/00, A61K 31/713, A61K 31/7088, A61P 29/00, A61P 25/28, A61P 25/00, C07K 16/28
US Classification:
4241341, 5303873, 5303892, 536 245, 4241581, 514 44 A, 5303896, 4241731
Abstract:
The present invention relates to therapeutic targets for multiple sclerosis and other inflammatory and neurological diseases. In particular, the present invention relates to altering G-CSF/G-CSFR signaling in the treatment of such disorders.
Compositions And Methods For Inhibiting Madcam
Compositions And Methods For Inhibiting Madcam
US Patent:
2011015, Jun 30, 2011
Filed:
Oct 4, 2010
Appl. No.:
12/897532
Inventors:
Benjamin M. Segal - Ann Arbor MI, US
Praveen Rao - Ann Arbor MI, US
Praveen Rao - Ann Arbor MI, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF MICHIGAN - Ann Arbor MI
International Classification:
A61K 39/395, C07K 16/00, A61K 31/713, A61P 29/00, A61P 25/28
US Classification:
4241331, 5303873, 514 44 A
Abstract:
The present invention relates to therapeutic targets for multiple sclerosis and neuroinflammatory diseases and injuries. In particular, the present invention relates to targeting MAdCAM in the treatment of such disorders.